Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Chng, Wee-Joo  [Clear All Filters]
2014
Zhou J, Chng W-J. Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia. World J Stem Cells. 2014;6(4):473-84.
2015
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2015.
Jiang X, Lim CZi Hui, Li Z, Lee PLeng, Yatim SMaryam JM, Guan P, Li J, Zhou J, Pan J, Chng W-J, et al. Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML). PLoS One. 2015;10(4):e0122983.
2022
Goh J, De Mel S, Hoppe MM, Rashid MBte Mohd A, Zhang XYun, Jaynes P, Ng EKa Yan, Rahmat N'ADiana Bint, Liu CXin, Poon L, et al. An ex vivo platform to guide drug combination treatment in relapsed/refractory lymphoma. Sci Transl Med. 2022;14(667):eabn7824.
2023
Gill H, Leung GMK, Ooi MGM, Z Y Teo W, Wong C-L, Choi CWon, Wong G-C, Lao Z, Rojnuckarin P, Castillo MRosario Ir, et al. Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group. Clin Exp Med. 2023.
Zhou J, Toh SHui-Min, Tan TKing, Balan K, Lim JQuan, Tan TZea, Xiong S, Jia Y, Ng S-B, Peng Y, et al. Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma. Mol Cancer. 2023;22(1):69.